Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT02434744

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Response Pharmaceuticals (from the registry)
Registry
  • NCT NCT02434744
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02434744. Randomized; quadruple masking; primary purpose treatment. Start 2015-04 (registry gives no type); primary completion 2016-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
KD026
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Lead sponsor
Response Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02434744
Content hash
c8f4f9db587080715683e6c74a19e4c028290b85ff1c78646a38f7a9b84ad5f6